174 results about "Intestinal juice" patented technology

The invention relates to the technical field of microorganisms, in particular to bifidobacterium bifidum BGLP1 capable of regulating sugar digestion and producing GLP-1 at high yield and application of the bifidobacterium bifidum BGLP1. The preservation number of the bifidobacterium bifidum BGLP1 is CGMCC (China General Microbiological Culture Collection Center) No.35718, and the bifidobacterium bifidum BGLP1 can be used for preparing the feed additive. The strain has the capability of inhibiting alpha-glucosidase and alpha-amylase; sTC-1 cells are stimulated to secrete GLP-1, and the blood glucose reducing pathway capacity of the intestinal tract is activated; the activity of pancreatic lipase is obviously inhibited, and the dietary fat absorption capability can be effectively reduced; redundant cane sugar is converted into exopolysaccharide, so that the probiotic function capability is improved; the capability of converting white fat into brown fat is promoted; macrophages are activated, and the body immune function is improved. In addition, the bifidobacterium bifidum BGLP1 also has relatively strong intestinal colonization ability, has good tolerance in artificial gastric juice and artificial intestinal juice, and can smoothly reach the intestinal tract of a human body.

The invention discloses a preparation method of a mycotoxin degrading enzyme intelligent slow-release feed additive, and relates to the technical field of feed additive production, a double-emulsion embedding technology is adopted, enzyme is embedded in a multi-layer shell composed of chitosan, sodium alginate and an enteric polymer Eudragit S100, and then Ca < 2 + > ion cross-linking solidification is performed to obtain the mycotoxin degrading enzyme intelligent slow-release feed additive. And finally, freeze-drying or spray-drying to obtain the core-shell structure microcapsule. The obtained microcapsules are compounded with functional carriers such as yeast cell walls, sodium aluminosilicate, mannan oligosaccharide, talcum powder and the like to prepare finished products which can be directly added into various feeds. The release rate of the additive in simulated gastric juice with the pH value of 2.0 for 4 hours is lower than 15%, the release rate of the additive in simulated intestinal juice with the pH value of 6.8 for 6 hours exceeds 90%, the enzyme activity can be effectively protected, and targeted release of intestinal tracts is achieved; meanwhile, the compound carrier has a synergistic adsorption effect on various mycotoxins, and the degradation rates of aflatoxin B1, zearalenone and ochratoxin A in an in-vitro experiment respectively reach 87% or above.

The invention belongs to the technical field of preparation of biological materials, and particularly discloses a sea cucumber flower self-assembled polypeptide-iron nano-carrier as well as a preparation method and application of the sea cucumber flower self-assembled polypeptide-iron nano-carrier. The preparation method comprises the following steps: dissolving freeze-dried sea cucumber flower powder in deionized water, adjusting the pH value to be alkaline, heating and stirring, centrifuging, discarding the precipitate, adjusting the pH value to be acidic, centrifuging, collecting the precipitate, and freeze-drying to obtain sea cucumber flower protein powder; preparing a reaction solution, adding simulated gastric juice and simulated intestinal juice, stirring for reaction, inactivating protease, centrifuging, taking supernatant, and freeze-drying to obtain sea cucumber flower self-assembled polypeptide; the preparation method comprises the following steps: preparing a solution from sea cucumber, adding FeCl2. 4H2O and ascorbic acid, adjusting the pH value to be acidic, carrying out heating reaction, centrifuging, discarding the supernatant, and freeze-drying to obtain the sea cucumber flower self-assembled polypeptide-iron nano-carrier. The invention discloses a sea cucumber flower self-assembled polypeptide-iron nano-carrier as well as a preparation method and application thereof. The carrier can promote absorption of an organism to iron, a relatively high iron ion release rate is maintained in an intestinal environment, and the in-vivo bioavailability of iron ions is improved.

The invention relates to a plant lactobacillus with effects of dispelling effects of alcohol, protecting the liver and restoring consciousness and application of the plant lactobacillus. The plant lactobacillus is a plant lactobacillus BGI-J9 strain, and the preservation number of the plant lactobacillus is CCTCC NO: M 20242630. The invention further discloses a preparation method of the plant lactobacillus with the effects of dispelling effects of alcohol, protecting the liver and restoring consciousness and application of the plant lactobacillus with the effects of dispelling effects of alcohol, protecting the liver and restoring consciousness. The strain has excellent tolerance to gastric acid, intestinal juice and cholate in a gastrointestinal tract system, can survive in the gastrointestinal tract, and provides a basis for continuously playing a probiotic effect; the compound has excellent inhibition capability on common intestinal pathogens; free radicals can be removed, and oxidative damage to the body is reduced; good alcohol metabolism enzyme synthesis capability and alcohol metabolism promoting potential are realized; the strain also has an excellent improvement effect on alcohol-damaged mice, specifically, the metabolism of ethanol and acetaldehyde in a body is accelerated, the occurrence time of drunkenness is obviously delayed, and the sobering time is shortened; intestinal injury and systemic inflammation caused by alcohol are improved; liver oxidative stress caused by alcohol is improved, and the occurrence and development process of alcoholic fatty liver is delayed; and cognitive function impairment caused by alcohol is improved.

The invention discloses a sea cucumber flower self-assembled polypeptide-selenium nano-carrier with antioxidant activity and a preparation method and application thereof, belongs to the technical field of functional protein peptides, and particularly relates to a preparation method of the sea cucumber flower self-assembled polypeptide-selenium nano-carrier with antioxidant activity, which comprises the following steps: heating a sea cucumber flower protein solution; the preparation method comprises the following steps: mixing sea cucumber with simulated gastric juice, reacting for 30-150 minutes, then adding simulated intestinal juice, reacting for 20-120 minutes, carrying out enzyme deactivation treatment, centrifuging, taking supernate, and freeze-drying to obtain sea cucumber flower self-assembled polypeptide; and mixing the sea cucumber flower self-assembled polypeptide with deionized water to prepare a sea cucumber flower self-assembled polypeptide solution, mixing the sea cucumber flower self-assembled polypeptide solution with a sodium selenite solution and a phosphate buffer solution, reacting for 20-60 minutes, washing with an ethanol solution, centrifugally collecting precipitate, and freeze-drying to obtain the sea cucumber flower self-assembled polypeptide-selenium nano-carrier. The sea cucumber flower self-assembled polypeptide-selenium nano-carrier prepared by the invention has good antioxidant activity and potential of effectively delivering selenium to an organism.

The invention relates to the technical field of medical instruments, in particular to a negative pressure flushing type rectal anastomotic fistula treatment device with a blocking balloon, which comprises a drainage tube, a balloon, an annular sponge sleeve, a water injection tube and a filling tube, the balloon is arranged at the near end of the drainage tube, and the filling tube is communicated with the balloon and used for filling media into the balloon to block an enteric cavity; the annular sponge sleeve wraps the outer side of the drainage tube below the balloon, and a side hole II is formed in the section, wrapped by the annular sponge sleeve, of the drainage tube; the water injection pipe is arranged on the drainage pipe and used for injecting flushing fluid into the annular sponge sleeve area. The far end of the drainage tube is used for being connected with a negative pressure device so that a continuous negative pressure drainage environment can be formed in the annular sponge sleeve area, the negative pressure flushing type rectum anastomotic fistula treatment device with the blocking balloon does not need to be placed under an endoscope and only needs to be placed under direct vision of an anoscope, and operation is easy; near-end intestinal juice can be blocked, and the influence of the intestinal juice on healing of an anastomotic stoma is reduced.

The plugging drainage device comprises an outer sleeve, a flushing pipe, an inner suction pipe and an umbrella-shaped plugging mechanism, a plurality of first through holes are formed in the front end of the outer sleeve, the inner suction pipe is arranged in the outer sleeve, a plurality of second through holes are formed in the front end of the inner suction pipe, and the umbrella-shaped plugging mechanism is arranged in the inner suction pipe. The umbrella-shaped plugging mechanism is arranged at the front end of the outer sleeve and can be retracted into the outer sleeve. The device is provided with the plugging mechanism, the fistula can be plugged during flushing, intestinal juice loss is effectively avoided, postoperative recovery of a patient is facilitated, the umbrella-shaped structure is adopted for plugging, compared with bag plugging, the umbrella fabric of the umbrella-shaped structure can be tightly attached to the wound surface, obstruction is effectively avoided, and the application safety of the device is further improved.

The invention provides a fish collagen peptide with a whitening effect and a preparation method thereof, and the method comprises the following steps: performing glycosylation modification treatment on fish collagen by using glucose, and then sequentially treating the fish collagen with gastric juice and intestinal juice to obtain the fish collagen peptide with a polypeptide sequence with glycosylation sites on a peptide chain. According to the invention, the fish collagen peptide with a remarkable inhibition effect on tyrosinase is obtained.

This invention belongs to the field of microbial technology, specifically relating to a strain of *Pediococcus pentosaceus* SUN02 with acetylcholinesterase inhibitory activity and its applications. This *Pediococcus pentosaceus* SUN02 is deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 29705. The *Pediococcus pentosaceus* SUN02 provided by this invention exhibits strong acid and bile salt resistance, good tolerance in simulated gastric and intestinal fluids, and can successfully reach the human intestine. *Pediococcus pentosaceus* SUN02, in its bacterial suspension and inactivated cells, possesses strong acetylcholinesterase inhibitory activity, produces γ-aminobutyric acid (GABA), and has antioxidant and other probiotic functions. Its application in probiotic products may help improve Alzheimer's disease, enhance learning and memory abilities, regulate mood, and improve sleep.

The invention relates to the technical field of biological medicine, and discloses bifidobacterium adolescentis YF-01 and application thereof in fermented milk. The bifidobacterium adolescentis YF-01 is separated from adult excrement and is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M 20251308. Experiments prove that the bifidobacterium adolescentis YF-01 has good gastrointestinal fluid tolerance, the survival rate of the bifidobacterium adolescentis YF-01 can reach 90.1% after simulated gastric fluid treatment for 3 h, and the survival rate of the bifidobacterium adolescentis YF-01 can reach 72% after simulated intestinal fluid treatment for 4 h The strain has the self-aggregation rate of 88.83% and the hydrophobicity of 79.41%, has remarkable scavenging capacity on DPPH free radicals and hydroxyl free radicals, shows good antioxidant activity and adhesion capacity, and provides a theoretical basis for application of the strain in fermented milk. The strain and metabolites thereof can be used for preparing food, medicines or health care products capable of regulating intestinal flora and enhancing oxidation resistance, and have remarkable application potential in development of functional fermented milk products.

The invention provides a pet hair decomposer with synergistic effect of bacillus subtilis and keratinase, the pet hair decomposer comprises bacillus subtilis ZYpet-015 and keratinase, the preservation number of the bacillus subtilis ZYpet-015 is CGMCC (China General Microbiological Culture Collection Center) No.34790, and the preservation date is June 6, 2025; the protease activity of the bacillus subtilis is greater than or equal to 129.92 U, the survival rate of the bacillus subtilis in simulated gastric juice within 3 hours is greater than 50%, and the tolerance rate of the bacillus subtilis in intestinal juice within 4 hours is greater than 90%. According to the pet hair decomposing agent, hair keratin is synergistically degraded through protease secreted by the bacillus subtilis ZYpet-015 and keratinase, and the hair decomposing efficiency reaches 28.07% + / -2.79% and is remarkably higher than that of a single treatment group. Meanwhile, experiments prove that the pet hair decomposer can effectively destroy the hair cuticle structure, is suitable for a pet hair-melting nutritional supplement and can relieve the hair ball symptom.

The invention relates to the field of medical apparatus and instruments in rectum surgery, and particularly provides a novel multifunctional intestinal bypass device for rectum surgery, which comprises a hollow sleeve, a film sleeve, a decompression air bag sleeved outside the hollow sleeve, and an inflation channel, wherein after being inflated, the decompression air bag protrudes in a corrugated or threaded mode in the axial direction of the hollow sleeve, the protruding part makes contact with the intestinal wall to provide friction force, and a decompression gap is formed between the sunken part and the intestinal wall; according to the invention, intestinal contents are discharged from the hollow sleeve and the film sleeve, so that excrement or intestinal juice is prevented from being in contact with an anastomotic stoma, the infection risk of the anastomotic stoma is reduced, and the healing rate of the anastomotic stoma is accelerated; the thin film sleeve is soft and deformable, so that discomfort such as anus falling expansion, pain and tenesmus of a patient can be effectively reduced, and the comfort of the patient is improved; the decompression air bag is expanded through the inflation channel, the hollow sleeve is positioned, meanwhile, blood supply of the intestinal wall is protected, and the reliable effect of replacing preventive fistulization is achieved.

The invention discloses a drug-loaded phase change microcapsule as well as a preparation method and application thereof. The drug-loaded phase change microcapsule comprises a phase change material matrix and polyelectrolyte particles filled in the phase change material matrix, the phase change material matrix comprises a phase change material and a hydrophobic drug, and the polyelectrolyte particles comprise deacetylated chitosan, soluble polysaccharide and a hydrophilic drug. According to the drug-loaded phase change microcapsule disclosed by the invention, efficient co-encapsulation of hydrophilic drugs and hydrophobic drugs is realized, collaborative delivery of drugs with different dissolvability can be carried out, protection on core drug components is improved, the microcapsule can be kept complete in gastric juice, and drugs can be released in intestinal juice through pH response and bile salt mediated micellization, so that the drug-loaded phase change microcapsule has the advantages that the drug-loaded phase change microcapsule has a good application prospect. A good gastrointestinal sustained-release function can be achieved, and the biological accessibility of active drugs is remarkably improved.

The invention belongs to the technical field of traditional Chinese medicine preparations, and provides a traditional Chinese medicine granule composition based on rhizoma polygonati and a preparation method and application thereof. A three-layer intelligent response structure design is adopted, a 80-300 nm rhizoma polygonati nano core is prepared through an anti-solvent precipitation technology, a calcium alginate gel buffer layer containing probiotic nutritional factors is constructed through an ionic crosslinking technology, a pH response shell layer is prepared through a fluidized bed coating technology, and the release rate lt in gastric juice is achieved; the cumulative release rate gt in intestinal juice is 10%; according to the invention, the rhizoma polygonati polysaccharide and probiotic nutritional factors are added into the preparation, the precise intestinal targeted release performance is 80%, the drug loading capacity is 15-35%, the coating efficiency is 85-95%, and the technical problems that a traditional rhizoma polygonati preparation is poor in stability, effective components are damaged by gastric acid, and the bioavailability is low are solved; the traditional Chinese medicine composition can be used for treating diseases such as weakness of the spleen and the stomach, functional dyspepsia and dysbacteriosis of intestinal flora, and has wide application value.

A rapid disintegration type enteric gelatin hollow capsule shell belongs to the technical field of hollow capsule production, and comprises the following components by mass: 70%-90% of gelatin, 0.01%-5.0% of a humectant, 0.01%-10% of a surfactant, 0.01%-10% of a plasticizer, 0-5% of a disintegrating agent, 0.1%-10% of an opacifying agent, and 1.0%-20% of a coating material. The method comprises the following steps: synchronously forming a glue solution and a coating, alternately dipping in glue, and drying at low temperature; the preparation method has the beneficial effects that a disintegration acceleration mechanism is adopted, the disintegrating agent quickly absorbs water and expands in intestinal juice, and the permeability of the capsule shell is enhanced by cooperating with the surfactant; the proportion of a coating material is optimized, and hydroxypropyl methylcellulose phthalate is greater than or equal to 15%, so that the intestinal juice response speed is increased; and the disintegration time in intestinal juice is about 8 minutes, which is increased by about 50% compared with the disintegration time of about 15 minutes of the traditional capsule.

The utility model discloses an intestinal juice perfusion testing device used before temporary fistulization reduction. The intestinal juice perfusion testing device comprises an outer shell with the hollow bottom, a perfusion assembly wrapped in the outer shell and a water pump assembly. One end of the filling assembly is plugged into the far end of the fistulization opening, and the other end is connected with a water outlet of the water pump assembly; the outer shell is semicircular, and the bottom of the outer shell is movably connected with the base plate of the two-piece fistulization bag. According to the intestinal juice perfusion testing device used before temporary fistulization and reduction, intestinal juice can be directly perfused into a far-end intestinal canal for temporary fistulization, the flowing condition of the intestinal juice in the natural state is simulated, and therefore the healing condition of a rectum anastomotic stoma, the recovery degree of the anus function and the adaptability of the colon function are evaluated more accurately.

The application discloses application of white ginseng mushroom in preparation of a medicine for treating hyperuricemia, and belongs to the technical field of deep processing of edible mushrooms. The white ginseng mushroom is vacuum freeze-dried, ground into powder, other traditional Chinese medicine ingredients are extracted, concentrated, and spray-dried into powder; the white ginseng mushroom powder is mixed with sodium carboxymethyl cellulose and guar gum solution to form a mushroom suspension colloid, the microcapsules are collected after being dropped into a calcium-containing aqueous solution; the microcapsules are immersed in a high polymer compound solution for treatment, finally mixed with a stabilizer paste, and then filled after being treated by a high-pressure homogenizer and sterilized. Compared with the prior art, the medicine has good stability in simulated gastric juice, can be quickly released in simulated intestinal juice, significantly improves the bioavailability and curative effect of the medicine, can effectively reduce the serum uric acid level, improve liver and kidney functions, and regulate the intestinal flora structure, and has a significant uric acid-lowering effect and multi-target synergistic effect.

This application relates to the field of functional composition technology, and in particular to a GABA-vitamin D neuroprotective composition and its preparation method, comprising medium-chain triglycerides, modified phospholipids, and a GABA-vitamin D blend. This application utilizes the low interfacial tension and strong amphiphilic compatibility of medium-chain triglycerides and modified phospholipids, enabling them to be miscible with the blend, thus improving the characteristics of GABA and vitamin D being easily degraded and oxidatively inactivated under complex physiological environments, and solving the problems of poor stability and asynchronous absorption. In the preparation method, the preferred component mass ratio is (0.6–1.5):1:(1–1.6), and mixing is carried out at 50–80°C for 10–60 min. The resulting system features high encapsulation efficiency, uniform particle size distribution, and high bioavailability. After treatment in simulated gastric fluid (pH 1.2) for 2 hours, the average GABA retention rate is ≥88% (optimal up to 94.3%), and the average vitamin D retention rate is ≥94% (optimal up to 96.8%). After treatment in simulated intestinal fluid (pH 6.8) for 4 hours, the simultaneous release rate of GABA and vitamin D is ≥90%, achieving precise intestinal delivery and making it suitable for industrial production.

The invention discloses a composite particle with a prebiotic function and colon-targeted co-delivery performance as well as a preparation method and application thereof, and belongs to the technical field of functional foods and intestinal micro-ecological regulators. According to the composite particle, the curcumin and the resveratrol are encapsulated by the peanut protein isolate to form a nano core, the outer layer of the nano core is a composite shell layer composed of the carboxymethyl konjac glucomannan and the prebiotics, a stable core-shell structure is formed, and the composite particle is small in particle size, good in dispersity and stability and good in stability. The stability of a protein-based delivery system in a gastrointestinal tract environment can be obviously improved; the release rate of the composite particles in simulated gastric juice and intestinal juice is low, and the composite particles can be specifically degraded and release active ingredients in simulated colon fluid containing beta-mannase, so that colon-targeted co-delivery can be realized. The composite particle disclosed by the invention is simple in preparation process and stable in function, can be applied to the fields of functional foods, health foods, formula foods for special medical purposes and the like, realizes dual purposes of active component delivery and intestinal microenvironment regulation, and has a wide application prospect.

This invention discloses a strain of Bifidobacterium animalis subspecies TRT-2A with allergy-relieving effects and its extracellular vesicle applications. The strain TRT-2A is deposited at the China Center for Type Culture Collection (CCTCC) on November 21, 2025, with accession number CCTCC NO:M 20252645. This strain is highly acid-resistant and exhibits good tolerance to artificial gastric and intestinal fluids. It effectively inhibits bacteria, particularly Streptococcus pyogenes, Streptococcus agalactiae, and / or Escherichia coli. Experimental results show that this strain can alleviate hormone-dependent dermatitis and effectively improve dermatitis symptoms such as erythema and desquamation. Furthermore, extracellular vesicles prepared using TRT-2A can effectively improve skin elasticity and reduce wrinkles. Therefore, the Bifidobacterium animalis subspecies TRT-2A of this invention has multiple functions and is worthy of further promotion and application.

The invention relates to a colon-targeted micro-ecological regulation composition. The colon-targeted micro-ecological regulation composition is prepared by compounding the following functional components in percentage by weight: 5-95% of a component A, 1-15% of a component B and 4-94% of a component C, the component A is resistant starch, the polymerization degree DP is greater than or equal to 15, and the crystallinity is greater than or equal to 35%; the component B is probiotics and is embedded through a complex coacervation method or an extrusion-gel method, the embedding rate is larger than or equal to 75%, and the particle size is 200-800 microns; the survival rate is greater than or equal to 60% after treatment in simulated gastric juice for 2 hours, and the survival rate is greater than or equal to 50% after treatment in simulated intestinal juice for 4 hours; the component C comprises functional nutritional auxiliary materials, the functional nutritional auxiliary materials comprise prebiotics and a medicinal and edible composition, and the prebiotics comprise rapid fermentation type prebiotics, medium-speed fermentation type prebiotics, slow fermentation type prebiotics and a non-fermentation type water-holding expansion component. By constructing a carbon source slow release-flora orientation-metabolism regulation ternary interaction collaborative network, accurate regulation and multi-target metabolism intervention of the whole digestive tract are realized.

The invention discloses application of schizophyllumcommuneh in preparation of a medicine for treating hyperuricemia, and belongs to the technical field of deep processing of edible mushrooms. Schizophyllumcommuneh is subjected to vacuum freeze drying and then ground into powder, and other traditional Chinese medicine components are subjected to extraction, concentration and spray drying to form powder; schizophyllumcommuneh powder is mixed with sodium carboxymethyl cellulose and a guar gum solution to form bacterial suspension colloid, the bacterial suspension colloid is dropped into a calcium-containing aqueous solution to be treated, and then microcapsules are collected; immersing the microcapsules into a high-molecular compound solution for treatment, finally mixing with stabilizer mucilage, treating by a high-pressure homogenizer, sterilizing and filling. Compared with the prior art, the medicine disclosed by the invention has good stability in simulated gastric juice and can be quickly released in simulated intestinal juice, the bioavailability and curative effect of the medicine are remarkably improved, the serum uric acid level can be effectively reduced, the liver and kidney functions can be improved, the intestinal flora structure can be adjusted, and the medicine has a remarkable uric acid reducing effect and a multi-target synergistic effect.

The application discloses a pH response core-shell structure encapsulated insulin nanomicelle and a preparation method thereof. The encapsulated insulin mass accounts for 91% of the total mass of the insulin dissolved in an acidic aqueous solution, and the encapsulated insulin mass accounts for 13% of the mass of the encapsulated insulin nanomicelle. The average particle size of the micelle is 190 nm, and the Zeta potential is -19 mV. The nanomicelle is stable, the encapsulation efficiency and the drug loading capacity of the encapsulated insulin are 91% and 13% respectively, the cumulative release of the insulin mass percentage in a simulated human gastric juice environment with pH=1.2 for 2 h, 4 h and 10 h is 12%, 14% and 20% respectively, and the release of the insulin mass percentage in a simulated human intestinal juice environment with pH=7.4 for 2 h and 10 h is 55% and 77% respectively. Compared with the pH response block located in the core of the encapsulated insulin nanomicelle, the pH response block located in the shell of the encapsulated insulin nanomicelle has high stability in the simulated human gastric juice and has a slow-release behavior in the simulated human intestinal juice, and is more suitable for the bioavailability of the oral insulin of the human body.

The invention provides bacillus licheniformis capable of producing amylase, protease and cellulase and application of the bacillus licheniformis. The bacillus licheniformis is bacillus licheniformis FJAT-27214 and is preserved in the China General Microbiological Culture Collection Center on August 6, 2025, the preservation address is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC No. 35536. The bacillus licheniformis disclosed by the invention can be used for simultaneously producing amylase, protease and cellulase at high yield; the bacillus subtilis has antibacterial activity to escherichia coli and has certain tolerance to artificial gastric juice, artificial intestinal juice and cholate, the survival rate in the artificial gastric juice is 58.11%, the survival rate in the artificial intestinal juice is 82.58%, and the survival rate in the cholate is 28.03%. When the strain fermentation liquor is used for pomace micro-storage, the content of crude protein and total sugar of pomace can be remarkably increased, meanwhile, the content of neutral detergent fiber and ammoniacal nitrogen is remarkably reduced, and an effective strain resource is provided for pomace micro-storage fermented feed.

The utility model discloses a balloon plugging catheter structure for colorectal surgery, which belongs to the technical field of catheter structure buckles and comprises a main catheter, the top end of the main catheter is connected with a positioning disc, the top end of the positioning disc is connected with a drainage component, the main catheter comprises a main tube, one end of the main tube is connected with a first balloon, and the other end of the main tube is connected with a second balloon. The other end of the main tube is connected with a second balloon, the bottom end of the second balloon is connected with a drainage tube, open holes are formed in the periphery of the drainage tube, the outer wall of one side of the drainage tube is connected with an auxiliary tube, and a folding opening is formed in the outer wall of one side of the auxiliary tube. The main tube part of the catheter structure is communicated with the corresponding saccules through each group of cavity tubes and can be matched with expansion of the two groups of saccules, double-end blocking is formed during placement and fixation, the sealing stability of the intestinal fistula part is improved, intestinal juice is prevented from overflowing, a subsequent secondary retraction operation is not needed, and the main tube part can be matched with connection of a traction rope to adjust the bending degree of a drainage tube; the intestinal inner wall is prevented from being attached during drainage, and drainage stability is kept.

Nanoemulsion composition for the treatment of inflammatory bowel diseases, comprising: a) 1.0% (w / w) curcumin as active pharmaceutical ingredient; b) 10.0% w / w Caprylic / Capric triglycerides as oil phase; c) 15.0% w / w Tween 80 as surfactant; d) 10.0% w / w PEG 400 as co-surfactant; e) 2.0% w / w lecithin as emulsifier; f) 2.0% w / w ethanol as a solubilizer; and g) distilled water qs to 100 w / w, h) wherein the composition forms a nanoemulsion having a mean particle size in the range of 90-120 nm and a polydispersity index of less than 0.3 and provides sustained curcumin release for at least 12 hours in simulated intestinal fluid.

This invention discloses a strain of *Bacillus parabrachium* ABX1 and its applications, belonging to the field of beneficial microbial technology. The *Bacillus parabrachium* ABX1 provided by this invention is a Gram-positive bacterium isolated from the intestinal fluid of *Bombyx mori*. On CMC-Na solid medium, the ratio of the diameter of the hydrolysis zone to the colony diameter can reach 11. Enzyme activity identification results show that the filter paper enzyme activity of *Bacillus parabrachium* ABX1 is as high as 109.79 U·mL. ‑1 The exo-β-glucanase activity was 107.59 U·mL. ‑1 The cellulase activity reached 107.37 U·mL ‑1 It exhibits excellent cellulose and / or crystalline cellulose degradation capabilities; it is easy to use and has a wide range of enzyme production conditions, showing excellent enzyme activity at pH 5–10 and 25–50℃; the enzyme production time is short, with high enzyme yield achieved in just 12 hours, and there is no significant adverse effect on enzyme yield with prolonged reaction time; it is highly safe to use and has great application prospects in areas such as oak garden waste branch treatment, improvement of oak silkworm digestibility, industrial degradation of cellulose, and improvement of soil fertility.

This invention discloses a strain of *Lactobacillus warfarinii* Z40 and its applications. The taxonomic name of *Lactobacillus warfarinii* Z40 is... Limosilactobacillus walteri Z40, deposited on May 18, 2026 at the China Center for Type Culture Collection (CCTCC), accession number CCTCC NO: M 20261007. This invention isolates a strain of *Lactobacillus warfarinii* Z40 from the intestines of healthy children. It exhibits certain resistance to gastric acid and high bile salts in intestinal fluid, and is non-hemolytic. Mouse model experiments have verified that it can effectively reduce the body weight of obese mice, decrease visceral fat accumulation, lower blood lipid levels, improve abnormal glucose metabolism in mice, and significantly reduce intestinal permeability, thereby improving abnormal phenotypes in mice in multiple ways. It can be applied to products related to weight loss, lowering blood lipids, lowering blood sugar, and improving intestinal barrier function.

The application discloses an automatic pressure regulating negative pressure suction device with automatic humidification function, which comprises a tracheal catheter, a closed sputum suction tube connected to the tail end of the tracheal catheter, a humidification tube connected to a humidification tube port on the closed sputum suction tube, an infusion device connected to the upper end of the humidification tube, sterile humidification liquid connected to the infusion device, a quantitative injection device additionally arranged outside a Murphy dropper of the infusion device, and a pressure pump provided with a volume sensor and a closed air bag wrapping the Murphy dropper, wherein the tail end of the closed sputum suction tube is connected to a disposable negative pressure suction liquid storage bottle through a suction device leather strap, and another connecting port of the negative pressure suction bottle is connected to a negative pressure suction pressure regulating table. According to the application, pressure modules are selected according to different suction liquids (sputum, bile, intestinal fluid, cerebrospinal fluid, etc.), a standard negative pressure value range is adjusted by one key, and the application is convenient to use. In addition, the automatic humidification can be performed on thick sputum for the sputum suction operation, the sputum is made to be thin, and the suction is facilitated.

The present application relates to the technical field of microorganisms, and particularly relates to a bifidobacterium BGLP1 capable of regulating sugar digestion and high GLP-1 production and application thereof. Bifidobacterium bifidum The bifidobacterium BGLP1 (CGMCC No. 35718) has the abilities of inhibiting alpha-glucosidase and alpha-amylase, stimulating STC-1 cells to secrete GLP-1 and activating the intestinal glucose-lowering pathway, significantly inhibiting pancreatic lipase activity and effectively reducing dietary fat absorption, converting excess sucrose into extracellular polysaccharides to increase the probiotic function, promoting the conversion of white fat into brown fat, and activating macrophages and improving the immune function of the body. In addition, the bifidobacterium BGLP1 has strong intestinal colonization ability, has good tolerance in artificial gastric juice and artificial intestinal juice, and can successfully reach the human intestinal tract.